drugset / Trial / NCT05807347
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG as induction regimen in Patients with Refreactory/Relapse Acute Myeloid Leukemia.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-02-01
- Completion
- 2026-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Background | Aclacinomycin | Unknown | 12 mg/m2 | — |
| Background | Aclacinomycin | Unknown | 14 mg/m2 | — |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |